Skip to main content

Table 1 Significant demographic, medical, and behavioral predictors of adherence to supervised exercise in the CARE Trial, 2008–2011, Canada

From: Predictors of adherence to different types and doses of supervised exercise during breast cancer chemotherapy

   Correlation1 ANOVA2
Variable M ± SD (%) r; p value F; p value
Group assignment   -.13; 0.025 3.1; 0.048
 Standard aerobic (n = 96) 78% ± 24%   
 Combined (n = 104) 71% ± 23%   
 High aerobic (n = 101) 70% ± 25%   
Location/Center   .42; <0.001 37.8; <0.001
 Ottawa (n = 84) 63% ± 27%   
 Edmonton (n = 117) 68% ± 23%   
 Vancouver (n = 100) 88% ± 13%   
Baseline Aerobic Exercise   .14; 0.015 5.1; 0.024
 Not meeting guidelines (n = 210) 71% ± 25%   
 Meeting guidelines (n = 91) 78% ± 21%   
Exercise limitations   -.10; 0.098 5.8; 0.017
 Not at all/a little (n = 150) 76% ± 22%   
 Somewhat/a lot/completely (n = 151) 70% ± 26%   
Comorbidities   -.04; 0.54 4.0; 0.047
 0 (n = 135) 76% ± 23%   
 ≥1 (n = 166) 70% ± 24%   
Length of chemotherapy protocol   -.13; 0.031 4.7; 0.031
 12 weeks (n = 89) 78% ± 21%   
 ≥18 weeks (n = 212) 71% ± 25%   
FEC-D3   -.14; 0.013 6.2; 0.013
 No (n = 200) 75% ± 22%   
 Yes (n = 101) 68% ± 27%   
  1. Note. 1Tested the association as a continuous variable. 2Tested the association as a predefined categorical variable. 3FEC-D = 5-fluorouracil, epirubicin, cyclophosphamide, docetaxel.